MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-...
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
About this item
Full title
Author / Creator
Hong, David S, Prof , Hui, David, MD , Bruera, Eduardo, Prof , Janku, Filip, MD , Naing, Aung, MD , Falchook, Gerald S, MD , Piha-Paul, Sarina, MD , Wheler, Jennifer J, MD , Fu, Siqing, MD , Tsimberidou, Apostolia M, MD , Stecher, Michael, MD , Mohanty, Prasant, MBBS , Simard, John, BSc and Kurzrock, Razelle, Prof
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Inflammation is an important feature of the malignant phenotype and promotes angiogenesis, tumour invasiveness, metastases, and cachexia. We used a first-in-class, monoclonal antibody (MABp1) cloned from a human being to target interleukin-1α, a mediator of chronic inflammation. We aimed to assess the safety and tolerability of M...
Alternative Titles
Full title
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1751212861
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751212861
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(14)70155-X
